3-methyl-5H,6H-benzo[h]cinnoline | 1616507-99-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-methyl-5H,6H-benzo[h]cinnoline
• 英文别名: 3-Methyl-5,6-dihydrobenzo[h]cinnoline
• CAS: 1616507-99-3
• 化学式: C₁₃H₁₂N₂
• 分子量: 196.252
• InChiKey: QCULITJPKONRQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-methyl-2-[(4-methylbenzene)sulfonyl]-2H,4aH,5H,6H-benzo[h]cinnoline 在 sodium acetate 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以54%的产率得到3-methyl-5H,6H-benzo[h]cinnoline
  参考文献：
  名称：

  From N-sulfonyl,C-homoallyl-hydrazones to pyrazole and pyridazine (N2)-heterocycles: the ultimate aromatization process

  摘要：

  Isomeric six- and five-membered (N-2)-aromatics, 6-methylpyridazines and 5-vinylpyrazoles, which energetic topological aromaticity is comparable to that of benzene, are shown to be efficiently produced by sequential isomerization elimination processes from the corresponding 6-methylidene-1,4,5,6-tetrahydropyridazines and 5-vinylpyrazolines, respectively. The latter precursors are available from the same N-sulfonyl,C-homoallyl-hydrazone substrates by a suitable choice of previously reported conditions for Pd-catalyzed CH-oxidative C,N-ring closing processes. The generality of these cyclization, isomerization, and aromatization reactions, for which detailed mechanisms are proposed, provides a systematic access to wide ranges of 3,4,6-trisubstituted 6-methyl-1,4-dihydropyridazines and 6-methylpyridazines, and their 3,4,5-trisubstituted 5-vinylpyrazole isomers. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.05.005

文献信息

• SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20150072959A1

  公开（公告）日：2015-03-12

  Substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

  本文揭示了替代三唑类化合物及含有该化合物的药物组合物，用于抑制受体蛋白酪氨酸激酶Axl的活性。还揭示了使用该化合物治疗与Axl活性相关的疾病或病状的方法。
• US8906922B2
  申请人：——

  公开号：US8906922B2

  公开（公告）日：2014-12-09
• US9353126B2
  申请人：——

  公开号：US9353126B2

  公开（公告）日：2016-05-31